1423-P: Glycemic Status at Three-Year Follow-up in LANDMARC—Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India

Abstract

Glycemic change from baseline to 3 years was examined in LANDMARC — a prospective observational study (CTRI/2017/05/008452) — that included participants with type 2 diabetes (T2D) taking ≥2 antihyperglycemic medications (with/without glycemic control). Of 6222 evaluable participants (mean baseline values - age: 52.1 years, T2D duration: 8.6 years and A1C: 8.05%), 5273 completed 3-year follow-up visit. All glycemic parameters improved significantly (p<0.0001) from baseline (A1C: -0.68% [1.65]; FPG: -16.51 mg/dL [55.38]; and PPG -27.07 mg/dL [80.10]). The number of participants in the 7-7.9% A1C subgroup increased from baseline to the end of 3 years; 21.79% (1356/6222) achieved optimum glycemic control of A1C <7%. Glycemic control was not affected by cardiovascular risk factors; while in the subgroups of complications, participants with myocardial infarction, heart failure, and unstable angina showed suboptimal glycemic control (Table). In conclusion, although there was a significant improvement in all the glycemic parameters from baseline, a large majority of the participants remained uncontrolled in terms of achieving target HbA1c. This emphasizes the need for optimizing diabetes management in India. Disclosure S.R.Joshi: Advisory Panel; Biocon, Zydus Cadila, Torrent Pharmaceuticals Ltd, Franco India, Consultant; Glenmark Pharmaceuticals, Twin Health, Speaker's Bureau; Abbott Nutrition, Sanofi, Abbott, Novo Nordisk, Lupin Pharmaceuticals, Inc. A.Sugumaran: Employee; Sanofi. A.Satpathy: Employee; Sanofi. A.Gadekar: Employee; Sanofi. S.K.Menon: Employee; Sanofi. R.Neogi: Employee; Sanofi. D.Chodankar: Employee; Sanofi. C.Trivedi: None. S.Wangnoo: None. A.H.Zargar: None. N.Rais: Advisory Panel; Bayer Consumer Care AG, Board Member; Abbott, Biocon. A.K.Das: n/a. K.Kumar: None. A.Mithal: Advisory Panel; Eris Lifesciences Ltd., Consultant; Glenmark Pharmaceuticals, Lupin Pharmaceuticals, Inc., USV Private Limited, Research Support; Sanofi, Speaker's Bureau; Novo Nordisk, Boehringer-Ingelheim, AstraZeneca, Sun Pharmaceutical Industries Ltd., Novartis. S.Kalra: Speaker's Bureau; Abbott, Bayer Inc., Novo Nordisk, Sanofi. A.Unnikrishnan: Speaker's Bureau; Sanofi, AstraZeneca, Boehringer-Ingelheim, Intas Pharmaceuticals Ltd. H.Thacker: None. B.Sethi: None. S.Chowdhury: None. Funding Sanofi India